Some tips to help get started:
There are 397 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.
397 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial targets patients with Stage IV NSCLC who have progressed after first-line chemoimmunotherapy and explores the combination of BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, with docetaxel.
ClinicalTrials.gov ID: NCT06841055
HealthScout AI summary: The trial targets adult patients with c-Met overexpressing, EGFR wild-type, non-squamous, locally advanced or metastatic NSCLC who have progressed after prior treatment, evaluating two regimens of telisotuzumab vedotin, an antibody-drug conjugate targeting c-Met by delivering the cytotoxic agent MMAE to tumor cells.
ClinicalTrials.gov ID: NCT06568939
HealthScout AI summary: This trial involves patients with advanced, recurrent, or metastatic solid tumors, such as esophageal cancer or NSCLC, that harbor a SMARCA4 mutation and have progressed on or are ineligible for standard therapies; it evaluates the investigational SMARCA2 degrader PRT3789 in combination with the PD-1 inhibitor pembrolizumab.
ClinicalTrials.gov ID: NCT06682806
HealthScout AI summary: The trial enrolls treatment-naïve patients with Stage IV squamous or non-squamous NSCLC and evaluates the combination of the HER3-DXd patritumab deruxtecan, an antibody-drug conjugate targeting HER3, with pembrolizumab, with or without platinum-based chemotherapy. Participants must have an ECOG performance status of 0 or 1 and meet specific health criteria for inclusion.
ClinicalTrials.gov ID: NCT06731907
HealthScout AI summary: This trial targets adult patients with advanced or metastatic solid tumors harboring RAS mutations, testing the safety and efficacy of IMM-1-104, a novel dual MEK1/2 inhibitor, as monotherapy or combined with mGnP or mFFX. Participants have conditions like PDAC, RAS-mutant melanoma, and NSCLC.
ClinicalTrials.gov ID: NCT05585320
HealthScout AI summary: This trial assesses the safety and efficacy of naporafenib, a pan-RAF kinase inhibitor, combined with trametinib, a MEK inhibitor, in patients aged 12 and older with previously treated, RAS Q61X-mutated locally advanced unresectable or metastatic solid tumors lacking standard treatment options. Patients with neurologically unstable primary CNS tumors or CNS metastases are excluded.
ClinicalTrials.gov ID: NCT05907304
HealthScout AI summary: This trial compares the combination of pembrolizumab and valemetostat tosylate, a dual EZH1/2 inhibitor, with pembrolizumab alone in patients with advanced or metastatic non-small cell lung cancer expressing PD-L1 ≥50% and lacking actionable genomic alterations. It includes patients who have not received prior systemic therapy and have a performance status of 0 or 1.
ClinicalTrials.gov ID: NCT06644768
HealthScout AI summary: The trial evaluates NC318, a Siglec-15-targeting monoclonal antibody, alone or with pembrolizumab in patients with advanced non-small cell lung cancer who have progressed following PD-1 inhibitor therapy or are PD-1 inhibitor naïve. It includes multiple treatment arms based on prior treatments and tumor PD-L1 expression levels.
ClinicalTrials.gov ID: NCT04699123
HealthScout AI summary: The trial involves adult patients with locally advanced or metastatic RAS-mutated NSCLC who have received prior standard therapy and are treated with investigational oral RAS(ON) inhibitors RMC-6236 and RMC-6291, targeting various RAS mutations, including KRAS G12C, in combination with standard treatments like pembrolizumab and chemotherapy agents.
ClinicalTrials.gov ID: NCT06162221
HealthScout AI summary: This trial involves patients with stage 4 metastatic non-small cell lung cancer who have not responded to at least two standard treatments, assessing the safety and efficacy of intravenous allogeneic gamma delta T-cell product, KB-GDT-01, combined with low-dose radiotherapy, aimed at enhancing the immune system's ability to recognize and destroy tumor cells.
ClinicalTrials.gov ID: NCT06069570